Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

L. Hauser, Stephen; Bar‐Or, Amit; Comı, Gıancarlo; Giovannoni, Gavin; Hartung, Hans‐Peter; Hemmer, Bernhard; Lublin, Fred; Montalbán, Xavier; Rammohan, Kottil; Selmaj, Krzysztof; Traboulsee, Anthony; S. Wolinsky, Jerry; L. Arnold, Douglas; Klingelschmitt, Gaëlle; Masterman, Donna; Fontoura, Paulo; Belachew, Shibeshih; Chin, Peter; Mairon, Nicole; Garren, Hideki; Kappos, Ludwig

doi:10.1056/nejmoa1601277

Public

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Published in New England Journal of Medicine • Dec 21, 2016

Authors:

Stephen L. Hauser

Amit Bar‐Or

Gıancarlo Comı

Abstract

BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS: In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous o...

Subject

Ocrelizumab

Medicine

Interferon beta-1a

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!